RBC Capital Reiterates Sector Perform Rating on Gilead Sciences, Inc. (GILD)

Market Context

Gilead Sciences, Inc. operates in the Healthcare sector. The stock currently trades at $131.76 with a market capitalization of $152.9B. The stock has gained 5.4% over the past 52 weeks.

Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Gilead Sciences, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Gilead Sciences, Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 05, 2026	RBC Capital	Sector Perform	N/A
Aug 05, 2026	Cantor Fitzgerald	Overweight	N/A
Aug 05, 2026	Needham	Buy	N/A
Jul 29, 2026	Barclays	Equal-Weight	N/A
Jul 27, 2026	Morgan Stanley	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View GILD Stock Page